Loading...
•
Dec 31, 2024
Alkermes Q4 2024 Earnings Report
Key Takeaways
Alkermes reported total Q4 2024 revenue of $430.0 million, up from $377.5 million in Q4 2023. Net income from continuing operations reached $145.7 million, while non-GAAP net income stood at $173.4 million. Adjusted EBITDA from continuing operations was $170.0 million. Revenue growth was driven by proprietary products, including VIVITROL, ARISTADA, and LYBALVI.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Revenue
CapyFin.comARISTADA Revenue
CapyFin.comLYBALVI Revenue
CapyFin.com Forward Guidance
Alkermes expects total revenue for 2025 to be between $1.34 billion and $1.43 billion, with continued growth in proprietary product sales. GAAP net income is projected to range from $175 million to $205 million.
Positive Outlook
- Expected strong revenue growth across proprietary products.
- Increased R&D investment to advance pipeline candidates.
- No outstanding long-term debt following full repayment in 2024.
- Improved operational efficiency driving profitability.
- Phase 2 trials for ALKS 2680 expected to report data in H2 2025.
Challenges Ahead
- Projected R&D expenses to increase to $305–$335 million in 2025.
- SG&A expenses expected to remain high at $655–$685 million.
- Potential headwinds from market competition in neuroscience sector.
- Expected cost of goods sold to range from $185–$205 million.
- Revenue from legacy products declining and expected to continue shrinking.
Revenue & Expenses
Visualization of income flow from segment revenue to net income